SCHEMBL2740532

SCHEMBL2740532

O=C(O)c1ccc2c(c1)C1(CC1)CC(c1cc(Cl)ccc1Cl)N2

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAG1 P54619 2/20 0.82
PRKAA1 Q13131 2/20 0.82
PRKAB1 Q9Y478 2/20 0.82
PRKAB2 O43741 1/20 0.82
PRKAA2 P54646 1/20 0.82
PRKAG3 Q9UGI9 1/20 0.82
PRKAG2 Q9UGJ0 1/20 0.82
IP6K1 Q92551 6/20 0.41
IP6K3 Q96PC2 1/20 0.40
IP6K2 Q9UHH9 1/20 0.40
TSHR P16473 1/20 0.36
SRD5A2 P31213 2/20 0.36
SRD5A1 P18405 1/20 0.36
KDM1A O60341 1/20 0.36
F11 P03951 3/20 0.35
F10 P00742 1/20 0.35
F7 P08709 1/20 0.35
CDC25B P30305 1/20 0.34
RARA P10276 1/20 0.34
RARB P10826 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2740533 0.90 PRKAG1 (1.00) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL2740545 0.87 PRKAG1 (0.64) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL2740546 0.87 PRKAG1 (0.63) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL41867 0.86 PRKAG1 (0.62) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL2740547 0.86 PRKAG1 (0.62) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL2740549 0.84 PRKAG1 (0.60) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL2740548 0.83 PRKAG1 (0.66) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL2740562 0.83 PRKAB2 (0.58) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL46885 0.82 PRKAG1 (0.69) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL2740550 0.80 PRKAG1 (0.55) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588458-B1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-06-04 EP disclosed
US-20120004218-A1 NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-01-05 US disclosed
US-20120004218-A1 NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-01-05 US disclosed
WO-2012001020-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004218-A1 NOVEL TETRAHYDRO-QUINOLINE DERIVATIVES GPR119, PRKAB1, PRKAG1 PRKAG1 3/4885PRKAA1 5/4885PRKAB1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.